Recent Updates — BCAB

BioAtla, Inc. reported that Dr. Eric Sievers resigned as Chief Medical Officer on September 25, 2026, to pursue outside interests while continuing as a consultant through June 30, 2027. His consulting agreement includes a one-time payment of $159,000 contingent on capital raising milestones by December 31, 2026, plus hourly compensation thereafter. The Board also reinstated retention and performance bonus programs for CEO Dr. Jay Short and CFO Christian Vasquez due to missed earlier milestones. Dr. Short’s target retention bonus is $440,892 and performance bonus is $220,000; Mr. Vasquez’s targets are $148,888 and $75,000 respectively. These payouts depend on financial and capital raising milestones achieved by December 31, 2026, or March 31, 2027. BioAtla operates in the biotechnology industry, focusing on developing antibody-drug conjugates for cancer treatment.

BioAtla, Inc. announced that the Nasdaq Listing and Hearing Review Council affirmed its decision to delist the company's common stock from The Nasdaq Capital Market due to non-compliance with minimum bid price and stockholders' equity requirements. Trading of the Common Stock is scheduled to be suspended at the opening of business on August 31, 2026, after which the shares will likely trade on the OTC Markets system under the symbol BCAB. The company noted that this delisting may have a material adverse effect on trading price and volume and expressed no assurance regarding the maintenance of an active market for its shares. BioAtla, Inc. operates in the biotechnology industry, focusing on the development of covalent antibody-based (CAB) technology platforms and product candidates.